Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.
September 10, 2020
This year, the 19th anniversary of the World Trade Center attacks on September 11th is especially painful. Brave heroes from Ground Zero are facing the added risk of COVID-19 infection. Newsday reports that more than 100 individuals in the large 9/11 community have died from COVID-19. The first responders who were exposed to toxic fumes and dust contracted serious lung diseases (along with cancers, including myeloma, as we have previously written about), and are now at high risk for COVID-19.
As we honor those who served so selflessly during that tragic event, let us not forget the unintended consequences and the precious lives that are being lost.
The best protections for those most vulnerable to the novel coronavirus remains a top priority. As the COVID-19 crisis reaches the six-month anniversary in the U.S., it is helpful to reflect on what we have experienced and what we have learned. Unfortunately, the truth hurts. Consider that:
The bottom line
The simple measures we have presented and discussed so many times here since the pandemic began are the first line of defense and will be essential in the U.S. for the foreseeable future.
Will the vaccines work well for myeloma patients?
This is the $64,000 question, as we hear about all the controversy surrounding the development of COVID-19 vaccines. The case of transverse myelitis, a serious autoimmune inflammation of the spinal cord, in the Astra Zeneca vaccine trial in the U.K., is a serious concern. Appropriately, this trial has been temporarily stopped.
There are several concerns for myeloma patients:
The bottom line
Myeloma patients will probably NOT be the first best candidates for vaccination until much more information is available.
A new report and commentary by Dr. Eric Topol again emphasize that there is marginal, if any, benefit with convalescent plasma treatment. The path forward with science is never easy. All trials are just that—TRIALS—to figure out if a treatment can help. Most trials do not work out. That is why we can truly celebrate when real breakthroughs occur. In the case of COVID-19, we are still waiting.
This week, as we remember 9/11, let us celebrate the spirit of the American people, who can rise to any occasion with self-sacrifice and honor. We must all do our best to stay safe in this time of COVID-19 and remember to help and protect those who are the most vulnerable. We WILL get through this together.
Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.